Lisata Therapeutics announces FDA ODD granted to LSTA1

Lisata Therapeutics announced the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to LSTA1, the Company’s lead product candidate, for the treatment of malignant glioma. “Malignant glioma is one of the most aggressive and deadly malignancies,” stated Kristen Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. “This Orphan Drug Designation acknowledges the high unmet medical need of this patient population as well as the potential of LSTA1 to benefit patients in this setting.”